Keyphrases
Parkinson's Disease
100%
Leucine-rich Repeat Kinase 2 (LRRK2)
50%
Mutation Carriers
43%
DYT6
20%
Glucocerebrosidase
20%
G2019S mutation
18%
Ashkenazi Jews
16%
Spatial Discrimination
15%
Discrimination Power
15%
Non-carriers
13%
G2019S
13%
Dystonia
13%
LRRK2 G2019S mutation
12%
Glucocerebrosidase mutations
11%
Patients with Parkinson's Disease
11%
Familial Parkinsonism
10%
Myeloid Cells
10%
Etiology
8%
GBA mutations
7%
Idiopathic Parkinson's Disease
7%
Parkinson Patients
7%
Age of Onset
6%
Monocytes
6%
Deep Brain Stimulation
6%
Tremor
6%
Mitochondrial Genes
5%
Dysregulation
5%
Unified Parkinson's Disease Rating Scale (UPDRS)
5%
Treatment Options
5%
Postural Instability Gait Difficulty
5%
Genetic Risk
5%
Olfactory Test
5%
Montreal Cognitive Assessment (MoCA)
5%
Olfaction
5%
Cancer Risk
5%
Essential Tremor
5%
Monoallelic
5%
Cognitive Functioning
5%
Glucosidase
5%
Sex-specific
5%
Dominican Republic
5%
Gait
5%
Puerto Ricans
5%
Dopa-responsive Dystonia
5%
Degenerative Cerebellar Ataxia
5%
Cognitive Effects
5%
β-acids
5%
Dystonic
5%
Diagnostic Test
5%
Enzyme Activity
5%
Neuroscience
Parkinson's Disease
83%
Dystonia
35%
Glucosylceramidase
21%
Leucine Rich Repeat Kinase 2
20%
Electrical Brain Stimulation
10%
Myeloid
10%
Tremor
7%
Mitochondrial Gene
5%
Anti-Inflammatory
5%
Diffusion Tensor Imaging
5%
Transcriptomics
5%
Antipsychotic
5%
Phenylalanine
5%
Enzyme Activity
5%
Voxel-Based Morphometry
5%
Parkinsonism
5%
Treatment of Pain
5%
Impulse Control Disorder
5%
Clozapine
5%
Subthalamic Nucleus
5%
Cognitive Effect
5%
Essential Tremor
5%
